AbbVie (NYSE: ABBV) announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), demonstrated a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Morgan Stanley Downgrades Abbvie (ABBV) to EqualweightJune 8, 2016 6:34 AM AbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLLJune 6, 2016 9:03 AM Cowen Cuts Abbvie (ABBV) to Market Perform; Analyst Calls Rova-T Data at ASCO 'Underwhelming'June 6, 2016 7:36 AM AbbVie (ABBV) Announces Positive ABT-414 Phase 1 Data in Aggressive Brain Cancer June 6, 2016 6:13 AM AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual MeetinJune 5, 2016 9:00 AM Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell LJune 5, 2016 7:30 AM Form 4 AbbVie Inc. For: Jun 02 Filed by: SEVERINO MICHAELJune 3, 2016 5:28 PM Form 4 AbbVie Inc. For: Jun 02 Filed by: GONZALEZ RICHARD AJune 3, 2016 5:27 PM AbbVie (ABBV) Plans Pipeline Update at R&D Day Event; Includes IMBRUVICA, ABT-484 DataJune 3, 2016 8:12 AM AbbVie to Highlight its Innovative Pipeline to the Investment CommunityJune 3, 2016 8:09 AM AbbVie (ABBV) Enters $3.8B Accelerated Stock Buyback AgreementJune 2, 2016 9:26 AM